Last reviewed · How we verify
Brinzolamide 1% ophthalmic suspension AZOPT®
Brinzolamide 1% ophthalmic suspension AZOPT® is a Small molecule drug developed by Alcon Research. It is currently FDA-approved. Also known as: AZOPT®, AZOPT.
At a glance
| Generic name | Brinzolamide 1% ophthalmic suspension AZOPT® |
|---|---|
| Also known as | AZOPT®, AZOPT |
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) (PHASE4)
- 24-hr Intraocular Pressure Control With SIMBRINZA ® (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brinzolamide 1% ophthalmic suspension AZOPT® CI brief — competitive landscape report
- Brinzolamide 1% ophthalmic suspension AZOPT® updates RSS · CI watch RSS
- Alcon Research portfolio CI
Frequently asked questions about Brinzolamide 1% ophthalmic suspension AZOPT®
What is Brinzolamide 1% ophthalmic suspension AZOPT®?
Brinzolamide 1% ophthalmic suspension AZOPT® is a Small molecule drug developed by Alcon Research.
Who makes Brinzolamide 1% ophthalmic suspension AZOPT®?
Brinzolamide 1% ophthalmic suspension AZOPT® is developed and marketed by Alcon Research (see full Alcon Research pipeline at /company/alcon-research).
Is Brinzolamide 1% ophthalmic suspension AZOPT® also known as anything else?
Brinzolamide 1% ophthalmic suspension AZOPT® is also known as AZOPT®, AZOPT.
What development phase is Brinzolamide 1% ophthalmic suspension AZOPT® in?
Brinzolamide 1% ophthalmic suspension AZOPT® is FDA-approved (marketed).
Related
- Manufacturer: Alcon Research — full pipeline
- Also known as: AZOPT®, AZOPT
- Compare: Brinzolamide 1% ophthalmic suspension AZOPT® vs similar drugs
- Pricing: Brinzolamide 1% ophthalmic suspension AZOPT® cost, discount & access